Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bullfrog dexamethasone adventitial infusion after infrapopliteal angioplasty
2015-002071-13Phase 3Terminated
- Sponsor
- Mercator MedSystems
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexamethasone in arteriosclerosis obliterans and chronic limb-threatening ischemia (CLTI), sponsored by Mercator MedSystems. Primary endpoints: Freedom from composite safety endpoint at 6 months, Freedom from major adverse limb events and 2 more. Started Sep 2016; status: terminated.
02
Drugs
dexamethasone
03
Conditions
arteriosclerosis obliteranschronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2015-002071-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002071-13.